TriSalus Life Sciences Q4 Earnings Call Highlights [Yahoo! Finance]
TriSalus Life Sciences, Inc. (TLSI)
Company Research
Source: Yahoo! Finance
million (up 53%), and is reaffirming 2026 revenue guidance of $60–$62 million with expected back-half weighting (~40% H1 / 60% H2). In February the company raised $46 million in a public offering and added investor Michael Stansky to the board, with proceeds earmarked to meaningfully double its commercial organization, fund comparative clinical studies, and accelerate product innovation. TriSalus launched several TriNav products (including TriNav XP and FLX) and expects TriNav Advance pending 510(k) in H1 2026; reimbursement gains (CMS code C8004 ), improving Q4 gross margin (87%) and a narrowed adjusted EBITDA loss (~$950k) support commercial momentum while cash stood at $20.4 million Interested in TriSalus Life Sciences, Inc.? Here are five stocks we like better. TriSalus Life Sciences (NASDAQ:TLSI) reported fourth-quarter and full-year 2025 results that management characterized as “strong,” driven by growth in its TriNav product suite and broader adoption of its Pressure-En
Show less
Read more
Impact Snapshot
Event Time:
TLSI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLSI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLSI alerts
High impacting TriSalus Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
TLSI
News
- TriSalus Life Sciences (TLSI) had its price target lowered by Canaccord Genuity Group Inc. from $12.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance [Yahoo! Finance]Yahoo! Finance
- TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue GuidanceBusiness Wire
TLSI
Earnings
- 3/5/26 - Miss
TLSI
Sec Filings
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- 2/26/26 - Form 424B5
- TLSI's page on the SEC website